Anuh Pharma Ltd share price is currently ₹83.39, up by ₹0.65 (0.79%) from its previous closing price of ₹82.74. The share price has gained 5.54% over the past month and declined -10.03% over the past year. The stock's 52-week low and high are ₹65.53 and ₹93.00, respectively. Anuh Pharma Ltd has a market capitalisation of ₹ 760.00 Cr. The share price was last updated on 28 Aug 2026, 10:23 AM IST.
Updated: 28 Aug 2026, 10:23:45 am IST
Mutual Fund Holder | Jun 26 Shares held | Jul 26 Shares held |
|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 752 | 769 (2.26%) |
| Bandhan BSE Healthcare Index Fund - Regular Plan - Growth | 385 | 413 (7.27%) |
Anuh Pharma Limited is engaged in the business of manufacturing and selling bulk drugs and chemicals. The Company's products include active pharmaceutical ingredients and corticosteroids. Its active pharmaceutical ingredients include macrolides, anti-TB, anti-malarial, antibacterial, anti-hypertension, expectorant, quinolones, intermediates and under development. Its macrolides products include erythromycin, erythromycin ethyl succinate, erythromycin stearate, erythromycin estolate, erythromycin propionate, erythromycin phosphate, and others. Its anti-malarial products include sulfadoxine, pyrimethamine, and others. The Company's anti-hypertension products include losartan potassium, telmisartan and atorvastatin calcium. The Company's corticosteroids include anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, antihistamines and under development. Its anti-inflammatory products include dexamethasone Na phosphate, mometasone furoate and clobetasol butyrate.
Insights from SEBI-registered analysts · updated live
Chahat Aggrawal
8 Feb • 9:33 PM · SEBI-Registered Analyst
Anuh Pharma Q3FY26: Revenue at ₹197.18 Cr, Margins Improve
💊 ANUHPHR reported solid Q3FY26 performance with unaudited revenue of ₹19,717.81 lakhs and net profit of ₹1,345.10 lakhs, reflecting improved margins and steady operational execution during the quarter.
Kundan Motwani
5 Dec • 1:50 PM · SEBI-Registered Analyst
💊 Anuh Pharma Secures Key Approval 🌍 ANUHPHR
Anuh Pharma Ltd has been granted a Certificate of Suitability (CEP) from EDQM for Sulfadimethoxine, an important API used in pharmaceutical formulations. Why this is significant 👇 • Enables broader access to highly regulated international markets • Strengthens global compliance & customer confidence • Opens opportunities for export growth in specialty APIs 📌 Listed stock to watch: Anuh Pharma Ltd — approval could improve long-term visibility & demand outlook. Indian API manufacturers continue gaining global traction. 🚀🇮🇳
See More
RA Anupam Bajpai
22 Oct • 4:28 PM · SEBI-Registered Analyst
ANUHPHR . – Bullish Outlook with Upside Target of ₹86
ANUHPHR ., a well-established player in the pharmaceutical sector, is showing signs of bullish momentum backed by both strong fundamentals and positive technical indicators. The company has demonstrated steady revenue growth over the past few years, reflecting consistent demand for its products and operational stability. Profitability metrics have improved recently, and with a low debt-to-equity ratio, the company maintains a solid financial position, providing a stable foundation for growth.
From a technical perspective, the stock is trading above its 50-day and 200-day moving averages, signaling a strong upward trend. The 14-day RSI is around 58, suggesting healthy buying interest without being overbought, while the MACD is positive, reinforcing the bullish momentum. Bollinger Bands show the price approaching the upper band, indicating strength while allowing room for controlled consolidation. These indicators collectively suggest continued upward movement in the near to medium term.
Considering Anuh Pharma’s stable financial performance, growth prospects, and favorable technical setup—including moving averages, RSI, MACD, and Bollinger Bands—the stock appears well-positioned for further gains. A realistic upside target of ₹86 is achievable, making it an attractive opportunity for investors looking for exposure to a fundamentally strong and technically supported pharmaceutical stock.
Shaly Gupta
11 Nov • 8:28 AM · SEBI-Registered Analyst
Stock in Focus
DOMS: Net profit at Rs 51.3 cr vs Rs 36.0 cr, Revenue at Rs 458 cr vs Rs 382 cr (YoY) (Positive) Healthcare Global: Net profit at Rs 18 cr vs Rs 13.6 cr, Revenue at Rs 552 cr vs Rs 486 cr (YoY) (Positive) Fortis: Net profit at Rs 193 cr vs Rs 184 cr, Revenue at Rs 1988 cr vs Rs 1770 cr (YoY) (Positive) Anuh Pharma: Net profit at Rs 15.0 cr vs Rs 13.8 cr, Revenue at Rs 166 cr vs Rs 149 cr (YoY) (Positive) Samhi: Net profit at Rs 12.6 cr vs loss Rs 88.0 cr, Revenue at Rs 265 cr vs Rs 220 cr (YoY) (Positive) Kovai Medical: Net profit at Rs 51 cr vs Rs 43 cr, Revenue at Rs 344 cr vs Rs 302 cr (YoY) (Positive) Manaksia: Net profit at Rs 1.7 cr vs Rs 1.2 cr, Revenue at Rs 151 cr vs Rs 100 cr (YoY) (Positive) GE Vernova: Net profit at Rs 145 cr vs Rs 37 cr, Revenue at Rs 1107 cr vs Rs 697 cr (YoY) (Positive) Alembic Ltd: Net profit at Rs 77 cr vs Rs 51 cr, Revenue at Rs 118 cr vs Rs 80 cr (YoY) (Positive) SCI: Net Profit at Rs 291 cr vs Rs 65.7 cr, Revenue at Rs 1450 cr vs Rs 1093 cr (Positive) Auro Pharma: Net Profit at Rs 817 crore versus poll Rs 930 crore, Revenues at Rs 7766 crore versus poll Rs 7757 crore (Neutral) LIC: Net profit at Rs 7728.68 cr vs Rs 8030.28 cr, NPR at Rs 120325.7 cr vs Rs 107876.8 cr (YoY) (Neutral) C E Info Systems: Net profit at Rs 30.3 cr vs Rs 33.0 cr, Revenue at Rs 104 cr vs Rs 91.0 cr (YoY) (Neutral) Ola Electric: Net Loss at Rs 495 cr vs Rs 495 cr, Revenue at Rs 1214 cr vs Rs 873 cr (YoY) (Neutral) Relaxo: Net profit at Rs 36.7 cr vs Rs 44.2 cr, Revenue at Rs 680 cr vs Rs 715 cr (YoY) (Neutral) Atul Auto: Net profit at Rs 4.6 cr vs Rs 7.1 cr, Revenue at Rs 181 cr vs Rs 153 cr (YoY) (Neutral) Dreamfolks Services: Net profit at Rs 17.1 cr vs Rs 18.1 cr, Revenue at Rs 320 cr vs Rs 280 cr (YoY) (Neutral) Steelcast: Net profit at Rs 13.3 cr vs Rs 18.6 cr, Revenue at Rs 76 cr vs Rs 101 cr (YoY) (Neutral) Welspun Corp: Net profit at Rs 290 cr vs Rs 385 cr, Revenue at Rs 3300 cr vs Rs 4060 cr (YoY) (Neutral)
See More
Sohrab Shaikh (SEBI RA)
15 Aug • 11:30 PM · SEBI-Registered Analyst
Ex Dividend date on 16-08-2024
1. Abirami Financial Services Rs. 2.5 per share 2. Alkali Metals Rs. 1 per share 3. Anuh Pharma Rs. 2.5 per share 4. Apollo Hospitals Rs. 10 per share 5. Astral Rs. 2.25 per share 6. Bata India Rs. 10 per share 7. Bella Casa Fashion Rs. 0.97 per share 8. Bharti Hexacom Rs. 4 per share 9. Capital Small Finance Bank Rs. 1.2 per share 10. Coal India Rs. 5 per share 11. Cochin Minerals & Rutile Rs. 8 per share 12. Comfort Fincap Rs. 0.1 per share 13. Comfort Intech Rs. 0.07 per share 14. Elcid Investment Rs. 25 per share 15. Elixir Capital Rs. 1.25 per share 16. Gland Pharma Rs. 20 per share 17. Godawari Power and Ispat Rs. 1.25 per share 18. Godrej Consumer Products Rs. 5 per share 19. Macrotech Developers Rs. 2.25 per share 20. NR Agarwal Industries Rs. 2 per share 21. Power Grid Corporation Rs. 2.75 per share 22. Thomas Cook Rs. 0.4 per share 23. Thyrocare Technologies Rs. 18 per share
See More
Today's market leaders and laggards
Exxaro Tiles Ltd
EXXARO
₹7.27
+1.20 (19.77%)
JG Chemicals Ltd
JGCHEM
₹655.81
+81.25 (14.14%)
Mastek Ltd
MASTEK
₹1,787.40
+202.13 (12.75%)
MV Electrosystems Ltd.
MVELECTRO
₹713.86
+73.19 (11.42%)
Xtranet Technologies Ltd.
XTRANET
₹179.94
+17.33 (10.66%)